⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
ApprovedThyroid

1%/15% ELITE IODINE BARRIER POST DIP

Formula Pending

Molecular Mass
N/A
CAS Registry
N/A
Risk Class
LOW
Last Audit
Jan 1, 2024

Research Abstract

Thyroid medication

1%/15% ELITE IODINE BARRIER POST DIP is a thyroid asset inside marketed initiatives, optimized for therapeutic and clinical research.

The dossier currently sits in approved with a low risk rating, meaning it is cleared for baseline monitoring protocols.

Supply records cite CAS N/A with updates logged 2024-01-01.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

TherapeuticClinical Research

Nomenclature

1%/15% ELITE IODINE BARRIER POST DIP

Reference Material

  1. [1] Anubis Compound Registry • CAS N/A
  2. [2] Operations Pulse • Marketed
  3. [3] Risk Governance Ledger • LOW clearance for 1-15-ELITE-IODINE-BARRIER-POST-DIP